This page was reviewed under our medical and editorial policy by
Maurie Markman, MD, President, Medicine & Science at CTCA.
This page was updated on February 3, 2022.
At Cancer Treatment Centers of America®(CTCA), we understand that you may want to see information regarding the survival results of patients with distant (also referred to as metastatic) stomach cancer who werediagnosedand/or at least initially partly treated at our hospitals to help you and your family decide where to go fortreatment,as part of many other factors you may be considering. Therefore, we asked an independent biostatistician to analyze thesurvival resultsof CTCA®patients.
Statistical methodology and limitations
Qualifications of the independent researchers
The chart below reflects the CTCA and SEER survival rates for stomach cancer patients with distant (metastatic) disease who were diagnosed between 2000 and 2015. It includes estimates of the percentage of stomach cancer patients with distant (metastatic) disease who survived for six months to five years after the initial diagnosis, as recorded in the CTCA and SEER databases.
The CTCA sample is relatively small because only metastatic stomach cancer patients who had been initially diagnosed at CTCA and/or received at least part of their initial course of treatment at CTCA were included. These factors significantly reduced the size of the CTCA sample, which means that the estimates reflected in the survival chart may be subject to high variation and may not be replicated in the future when we have a larger CTCA sample for analysis.
為一個完整的、技術methodolo的解釋gy used in the analyses and a detailed description of the CTCA and SEER patient groups included,click here to view statistical methodology, and for more information about the SEER program, go toseer.cancer.gov.
We also want to be sure you understand that cancer is a complex disease and each person’s medical condition is different; therefore, CTCA makes no claims about the efficacy of specific treatments, the delivery of care, nor the meaning of the CTCA and SEER analyses. Not all cancer patients who are treated at a CTCA hospital may experience these same results.
How COVID-19 affects your cancer treatment
Take our COVID-19 assessment